Market Overview

LivaNova Concludes PRELUDE Study for Transcatheter Mitral Valve Replacement System


Company now focused on INTERLUDE CE Mark trial, building upon
positive patient outcomes

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology
company, today announced the conclusion of the PRELUDE feasibility study
for its Caisson Transcatheter Mitral Valve Replacement (TMVR) system.
The PRELUDE first-in-human study evaluated the Company's TMVR system to
treat moderate to severe mitral regurgitation (MR) using a transseptal
approach. This is a less invasive approach using a tube (catheter)
through an incision in the groin, instead of an opening in the chest, to
replace a patient's mitral valve. Following the positive patient
outcomes from the PRELUDE study, the Company will now focus on enrolling
patients in the INTERLUDE CE Mark trial and finalizing the protocol for
the U.S. pivotal trial, ENSEMBLE, with the U.S. Food and Drug
Administration (FDA).

"Patients with moderate to severe mitral regurgitation are often too
sick for traditional open-heart surgery. We saw encouraging outcomes in
patients within the PRELUDE trial. Follow-up results showed positive
acute valve performance, which was maintained over time, along with
improved quality of life," said Principal Investigator Dr. Mathew
Williams, Chief of Adult Cardiac Surgery and Director of the Heart Valve
Program at NYU Langone Health. Williams, who has performed the most
LivaNova TMVR implants to date, added, "We are pleased to continue our
TMVR research with the INTERLUDE trial."

MR is a condition in which a patient's mitral valve does not close
tightly, allowing blood to flow backward into the heart. As a result,
blood cannot move through the heart or to the rest of the body as
efficiently, causing fatigue and shortness of breath. Only a small
percentage of the millions of people with moderate to severe MR are
treated because of prohibiting factors that can include advanced age,
impaired heart function and multiple comorbidities.1,2

"At LivaNova, we believe our transseptal approach for TMVR is an ideal
and less invasive treatment option for patients who suffer from mitral
regurgitation, since they are typically very ill. The initial PRELUDE
study results have been meaningful and suggest that our TMVR system is
durable over time, while demonstrating its fully repositionable and
retrievable capabilities," said Paul Buckman, LivaNova General Manager
of TMVR.

The INTERLUDE trial will be conducted in North American and European
centers with enrollment completion expected by 2020.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova's advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London, LivaNova has a presence in more than 100 countries worldwide.
The Company currently employs approximately 4,000 employees.
LivaNova operates as two businesses: Cardiac Surgery and
Neuromodulation, with operating headquarters in Mirandola (Italy)
and Houston (U.S.A.), respectively.

For more information, please visit

Safe Harbor Statement

This news release contains forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as amended,
and Section 21E of the United States Securities Exchange Act of 1934, as
amended. Forward-looking statements are not historical facts but are
based on certain assumptions of management and describe LivaNova's
future plans, strategies and expectations. Forward-looking statements
can generally be identified by the use of forward-looking terminology,
including, but not limited to, "may," "could," "seek," "guidance,"
"predict," "potential," "likely," "believe," "will," "expect,"
"anticipate," "estimate," "plan," "intend," "forecast," or variations of
these terms and similar expressions, or the negative of these terms or
similar expressions. Forward-looking statements contained in this news
release are based on information presently available to LivaNova and
assumptions that LivaNova believes to be reasonable, but are inherently
uncertain. As a result, LivaNova's actual results, performance or
achievements may differ materially from those expressed or implied by
these forward-looking statements, which are not guarantees of future
performance or actions that may be taken by LivaNova and involve known
and unknown risks, uncertainties and other factors that are, in some
cases, beyond LivaNova's control. You should carefully consider the
risks and uncertainties that affect LivaNova, including those described
in the "Risk Factors" section of LivaNova's Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other
documents filed from time to time with the United States Securities and
Exchange Commission.

All information in this news release is as of the date of its release.
LivaNova does not undertake or assume any obligation to update publicly
any of the forward-looking statements in this news release to reflect
actual results, new information or future events, changes in assumptions
or changes in other factors affecting forward-looking statements, except
to the extent required by applicable law. If we update one or more
forward-looking statements, no inference should be drawn that we will
make additional updates with respect to those or other forward-looking
statements. We caution you not to place undue reliance on any
forward-looking statements, which are made only as of the date of this
news release.

1. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart
Association Statistics Committee and Stroke Statistics Subcommittee.
Heart disease and stroke statistics—2010 update: a report from the
American Heart Association. Circulation. 2010; 121(7):e46-e215.

2. Mirabel M, Iung B, Baron G, et al. What are the
characteristics of patients with severe, symptomatic, mitral
regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358-1365.

View Comments and Join the Discussion!